Athira Pharma’s experimental Alzheimer’s drug fosgonimeton hit a speedbump on its way toward FDA approval: The treatment failed to show a clinical benefit in…
In February, Biogen announced it was pulling Aduhelm off the market. The company will continue supplying the drug until November but stopped providing it…
Members of the Being Patient community are increasingly curious to learn their genetic status as it relates to Alzheimer’s risk. A story I was…
With the 2024 FDA approval of Eli Lilly’s Kisunla for early-stage Alzheimer’s disease, there are now two fairly similar anti-amyloid on the market in…
During the Alzheimer’s Association International Conference in Philadelphia last week, researchers and drug companies presented data on a range of different Alzheimer’s drugs. Amidst…
On July 25th, European regulators said no to Eisai and Biogen’s anti-amyloid drug Leqembi for early stage Alzheimer’s. The European Medicines Agency (Europe’s version…
In a recent survey, Being Patient put a question to readers: “What is the biggest barrier preventing you from seeking a trial?” The most…
Cassava Sciences’ experimental Alzheimer’s drug simufilam is currently in clinical trials. Meanwhile, the company is experiencing a major shake-up. Its CEO and lead neuroscientist…
A new drug for Alzheimer’s was just this month approved by the FDA for use in the United States, in people in the earliest…
There are more than 500 active clinical trials for Alzheimer’s and other dementias in the U.S. They are designed to test different interventions, such…
UPDATED JULY 3: The Food and Drug Administration has approved Kisunla (generic name donanemab), a new Alzheimer’s drug developed by Eli Lilly. The published data…
A new anti-amyloid drug for Alzheimer’s disease might receive FDA approval as soon as this month. Although anti-amyloid drugs have shown us that clear…
Drugmaker Alzheon is currently running clinical trials on a new disease-modifying Alzheimer’s treatment: valiltramiprosate, or ALZ-801. While, like the new buzzy new Alzheimer’s monoclonal…
Today, the Food and Drug Administration’s (FDA) eleven-person advisory committee unanimously voted, (11-0) that Eli Lilly’s anti-amyloid Alzheimer’s drug donanemab was effective, and that…
Across Alzheimer’s disease and other dementias, protein plaques and deposits in the brain — like beta-amyloid, tau, and TDP-43 — are linked to inflammation,…